Enhanced Cancer Cell Growth Inhibition by Dipeptide Prodrugs of Floxuridine: Increased Transporter Affinity and Metabolic Stability

Molecular Pharmaceutics - Tập 5 Số 5 - Trang 717-727 - 2008
Yasuhiro Tsume1, John M. Hilfinger1, Gordon L. Amidon1
1Department of Pharmaceutical Science, University of Michigan, Ann Arbor, Michigan 48109, and TSRL, Inc., Ann Arbor, Michigan 48108

Tóm tắt

Từ khóa


Tài liệu tham khảo

Han H. K., 1998, Pharm. Res., 15, 1382, 10.1023/A:1011945420235

Song X., 2005, J. Med. Chem., 48, 1274, 10.1021/jm049450i

Song X., 2005, Mol. Pharmaceutics, 2, 157, 10.1021/mp049888e

Friedrichsen G. M., 2002, Eur. J. Pharm. Sci., 16, 1, 10.1016/S0928-0987(02)00047-7

Guo A., 1999, J. Pharmacol. Exp. Ther., 289, 448

Anand B. S., 2003, J. Pharmacol. Exp. Ther., 304, 781, 10.1124/jpet.102.044313

Landowski C. P., 2003, J. Pharmacol. Exp. Ther., 306, 778, 10.1124/jpet.103.051011

Umapathy N. S., 2004, Pharm. Res., 21, 1303, 10.1023/B:PHAM.0000033019.49737.28

Phan D. D., 2003, Antimicrob. Agents Chemother., 47, 2351, 10.1128/AAC.47.7.2351-2353.2003

Nishizawa Y., 1965, Biochem. Pharmacol., 14, 1605, 10.1016/0006-2952(65)90015-8

Vig B. S., 2003, Pharm. Res., 20, 1381, 10.1023/A:1025745824632

Kawaguchi T., 1985, Chem. Pharm. Bull. (Tokyo), 33, 1652, 10.1248/cpb.33.1652

Landowski C. P., 2005, Pharm. Res., 22, 1510, 10.1007/s11095-005-6156-9

Landowski C. P., 2005, Mol. Cancer Ther., 4, 659, 10.1158/1535-7163.MCT-04-0290

Han H., 1998, Pharm. Res., 15, 1154, 10.1023/A:1011919319810

Rubio-Aliaga I., 2002, Trends Pharmacol. Sci., 23, 434, 10.1016/S0165-6147(02)02072-2

Anand B. S., 2004, J. Pharmacol. Exp. Ther., 311, 659, 10.1124/jpet.104.069997

Meredith D., 2000, Eur. J. Biochem., 267, 3723, 10.1046/j.1432-1327.2000.01405.x

Surendran N., 1999, Pharm. Res., 16, 391, 10.1023/A:1018821718340

Wenzel U., 1996, J. Pharmacol. Exp. Ther., 277, 831

Wenzel U., 1995, Br. J. Pharmacol., 116, 3021, 10.1111/j.1476-5381.1995.tb15958.x

Nielsen C. U., 2001, J. Controlled Release, 76, 129, 10.1016/S0168-3659(01)00427-8

Satake M., 2002, Biosci. Biotechnol. Biochem., 66, 378, 10.1271/bbb.66.378

Weller S., 1993, Clin. Pharmacol. Ther., 54, 595, 10.1038/clpt.1993.196

Gonzalez D. E., 1998, Cancer Res., 58, 519

Kim I., 2003, J. Biol. Chem., 278, 25348, 10.1074/jbc.M302055200

Kim I., 2004, Mol. Pharmaceutics, 1, 117, 10.1021/mp0499757

Laskin J. D., 1979, Cancer Res., 39, 383

Yamada M., 1998, J. Neurooncol., 37, 115, 10.1023/A:1005869226496

Grem J. L., 2000, Invest. New Drugs, 18, 299, 10.1023/A:1006416410198

Parker W. B., 1990, Pharmacol. Ther., 48, 381, 10.1016/0163-7258(90)90056-8

van Laar J. A., 1998, Eur. J. Cancer, 34, 296, 10.1016/S0959-8049(97)00366-3

Willmore E., 1993, Biochem. Pharmacol., 46, 205, 10.1016/0006-2952(93)90405-L

Birnie G. D., 1963, Biochemistry, 2, 566, 10.1021/bi00903a031

Vabeno J., 2004, J. Med. Chem., 47, 1060, 10.1021/jm031022+

Doring F., 1998, J. Biol. Chem., 273, 23211, 10.1074/jbc.273.36.23211

Terada T., 1999, Am. J. Physiol., 276, G1435

Anand B. S., 2002, Expert Opin. Biol. Ther., 2, 607, 10.1517/14712598.2.6.607

Steingrimsdottir H., 2000, Antimicrob. Agents Chemother., 44, 207, 10.1128/AAC.44.1.207-209.2000

Ganapathy M. E., 1998, Biochem. Biophys. Res. Commun., 246, 470, 10.1006/bbrc.1998.8628

Eriksson A. H., 2005, Mol. Pharmaceutics, 2, 242, 10.1021/mp050015+

Li J., 1998, J. Drug Targeting, 5, 317, 10.3109/10611869808997860

Tamura K., 1996, Pharm. Res., 13, 1213, 10.1023/A:1016068421243

Lorenzi P. L., 2005, J. Pharmacol. Exp. Ther., 314, 883, 10.1124/jpet.104.082412

Larsen S. W., 2004, Eur. J. Pharm. Sci., 22, 399, 10.1016/j.ejps.2004.04.013

Goolcharran C., 1998, J. Pharm. Sci., 87, 283, 10.1021/js970325m

Jensen E., 1991, Int. J. Pharm., 71, 117, 10.1016/0378-5173(91)90073-W

Beauchamp L. M., 1992, Antiviral Chem. Chemother., 3, 157, 10.1177/095632029200300305

Woodman P. W., 1980, Cancer Res., 40, 507